DEKK-TEC, INC.

Basic Information

725 TOPAZ STREET
NEW ORLEANS, LA, 70124-

Company Profile

R & D drug development

Additional Details

Field Value
DUNS: 139242184
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN): A Phase II Clinica

    Amount: $1,161,453.00

    DESCRIPTION (provided by applicant): The principal goal of this research project will be to evaluate 4-demethyl-4- cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN), a polychlorinated cholesterol carbo ...

    SBIR Phase II 2013 Department of Health and Human Services
  2. Camptothecin Analogs for Cancer Therapy

    Amount: $837,217.00

    DESCRIPTION (provided by applicant): 7-Butyl-10-aminocamptothecin (BACPT), as a water-soluble dipeptide pro-drug - BACPTDP, is a novel camptothecin analog that has increased activity in hypoxic/acidic ...

    SBIR Phase II 2010 Department of Health and Human Services
  3. 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) Phase I Clinical Tr

    Amount: $272,657.00

    DESCRIPTION (provided by applicant): The object of the proposed research is to conduct a Phase 1 clinical trial with 4-demethyl-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN), a carbonate derivative ...

    SBIR Phase I 2008 Department of Health and Human Services
  4. Camptothecin Analogs for Cancer Therapy

    Amount: $158,895.00

    DESCRIPTION (provided by applicant): 7-butyl-10-aminocamptothecin (BACPT) and its water-soluble dipeptide pro-drug, are novel camptothecins that were designed to be used in the treatment of childhood ...

    SBIR Phase I 2007 Department of Health and Human Services
  5. SBIR TOPIC 232 MANUFACTURE OF 4-DEMETHYL 4-CHOLESTEROLYL-PENCLOMEDINE

    Amount: $150,000.00

    N/A

    SBIR Phase I 2007 Department of Health and Human Services
  6. Clinical Development of 4-Hydroperoxyifosfamide

    Amount: $539,124.00

    DESCRIPTION (provided by applicant): 4-Hydroperoxyifosfamide (HOO-IFOS) is a stable, pre-activated form (peroxide) of 4-HO-IFOS, the initial metabolite of Ifosfamide (IFOS). Under physiological condit ...

    SBIR Phase II 2006 Department of Health and Human Services
  7. A-007: Immune Modulation of HPV- Associated Neoplasia

    Amount: $2,300,487.00

    DESCRIPTION (provided by applicant): 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) was originally developed as an immune modulator of immune deficiency associated cancerous growths. In ...

    SBIR Phase II 2005 Department of Health and Human Services
  8. CLINICAL DEVELOPMENT OF 4-HYDROPEROXYIFOSFAMIDE

    Amount: $185,641.00

    DESCRIPTION (provided by applicant): The objective of the proposed research is to synthesize 4-hydroperoxyifosfamide (HOO-IFOS) in sufficient quantity for evaluation in vivo against a human osteosarc ...

    SBIR Phase I 2002 Department of Health and Human Services
  9. A-007: IMMUNE MODULATION OF HPV- CERVICAL CANCER

    Amount: $191,517.00

    DESCRIPTION: (Applicant's Description) 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) has recently completed a Phase I clinical t ...

    SBIR Phase I 2001 Department of Health and Human Services
  10. N/A

    Amount: $0.00

    N/A

    SBIR Phase I 2000 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government